Free peptides to try with every order over $100
ARA-290 product image

ARA-290

Compounded in a licensed US 503A pharmacy 🇺🇸

Tissue Support Research Peptide.

$60
In stock2-day shipping, discreet
Choose your bundle
1
Secure checkoutDiscreet packagingThird-party tested

ARA-290 (also known as Cibinetide) is a synthetic peptide engineered from erythropoietin to selectively bind the innate repair receptor (IRR) without engaging the classical EPO receptor. Laboratory researchers investigate it in models of tissue stress, nerve signaling, and inflammatory pathway modulation. Preclinical studies have explored its interaction with small-fiber neural circuits and metabolic stress responses in controlled settings. Supplied as a lyophilized peptide of analytical purity for in vitro and preclinical research only. Store refrigerated and reconstitute under aseptic laboratory conditions.

Why you'll like it
  • 10mg research vial
  • Lyophilized for stability
  • Research-grade compound
  • Laboratory research only
≥99%
HPLC purity
Certificate of analysis
Third-party tested. Every batch.

Independently verified by Freedom Diagnostics via HPLC and mass spec. Every vial carries a unique accession number you can look up directly with the lab.

Verify COA · Freedom Diagnostics
In every order
Peptide vial(s)
Alcohol prep pads
Storage guide
Shipping & returns
  • 2-day shipping nationwide, flat $12.50
  • Plain, discreet packaging. No product names on the outside.
  • Tracking emailed the moment your order ships.
Form
Lyophilized powder
Molecular Formula
C38H65N11O9
Molar Mass
820.0 g/mol
Overview

About ARA-290

ARA-290 (also known as Cibinetide) is a synthetic peptide derived from the helical region of erythropoietin (EPO) that is specifically engineered to interact with the innate-repair receptor (IRR) rather than the classical EPO receptor. Researchers designed this compound to separate the tissue-protective properties of EPO from its hematopoietic activity, yielding a molecule studied primarily for its interactions with neural and metabolic pathways in laboratory models.

In preclinical research, ARA-290 has been investigated for its role in modulating inflammatory signaling cascades. Studies have explored how the compound engages the beta common receptor subunit in contexts such as peripheral nerve function and pancreatic beta-cell survival. Its selectivity profile makes it a subject of interest in laboratories examining how EPO-derived sequences interact with non-hematopoietic tissues.

As a lyophilized research peptide, ARA-290 is handled under controlled laboratory conditions. Researchers typically reconstitute it in sterile aqueous buffer for in vitro and preclinical in vivo model use. The compound is not intended for human or veterinary clinical use and is supplied exclusively for scientific investigation.

Ordering & shipping

Buy ARA-290 online

ARA-290 (Cibinetide) is in stock and available to buy online from Optimum ReGen Peptides — a real American research-peptide company with a physical storefront in Medford, Oregon, not an anonymous overseas dropshipper. Priced from $60, every order ships within two business days, flat $12.50 nationwide, in plain discreet packaging with tracking.

As your ARA-290 supplier we back every batch with a third-party certificate of analysis and compound in a licensed US 503A pharmacy. Vials are supplied lyophilized at analytical purity for laboratory and research use only, not for human consumption.

Research context

Researched For

01
Peripheral neuropathy models

ARA-290 has been studied in rodent models of peripheral nerve injury, with researchers examining its interactions with small fiber neuropathy endpoints and nerve conduction parameters.

02
Pancreatic beta-cell biology

Laboratory investigations have explored whether ARA-290 engages protective signaling pathways in isolated beta cells and islet preparations under inflammatory challenge conditions.

03
Inflammatory pathway modulation

Studies have characterized ARA-290's interactions with cytokine signaling networks, particularly its reported capacity to attenuate pro-inflammatory marker expression in cell-based assays.

04
Sarcoidosis-related small fiber neuropathy research

Preclinical and early exploratory research has used ARA-290 to investigate innate-repair receptor engagement in models relevant to small-fiber damage associated with systemic inflammatory conditions.

05
Metabolic syndrome models

Researchers have examined ARA-290 in high-fat-diet animal models, studying its effects on insulin sensitivity markers and adipose tissue inflammatory indicators at the cellular level.

Methodology

How It Is Studied

ARA-290 is typically administered in preclinical models via subcutaneous or intraperitoneal routes at nanomolar to low micromolar concentrations. Researchers use ELISA-based cytokine profiling, immunohistochemistry of nerve tissue cross-sections, and electrophysiological measurements to characterize downstream effects following compound exposure in relevant animal models.

In cell-based assays, ARA-290 is applied to cultured neuronal cell lines, primary Schwann cells, and pancreatic islet preparations to study receptor binding kinetics and intracellular signaling responses including STAT3 and NF-kB pathway modulation. Confocal imaging and Western blot analysis are standard readouts used to quantify pathway engagement.

Researchers studying its selectivity profile use receptor binding competition assays comparing ARA-290 to full-length EPO, confirming that the peptide does not stimulate erythropoiesis at the concentrations used in tissue-protective studies. This mechanistic separation is a central focus of publications in the field.

Technical sheet

Specifications

Technical data sheetResearch grade
FormLyophilized powder
Purity>= 99% (HPLC)
Molecular FormulaC38H65N11O9
Molar Mass820.0 g/mol
Storage (lyophilized)-20 °C, protected from light
Storage (reconstituted)4 °C, use within 7 days
For research use only. Not for human consumption.
Storage protocols

Storage & Handling

Lyophilized ARA-290 should be stored at -20 °C in a desiccated environment away from direct light. The powder form is stable for extended periods under these conditions. Once reconstituted in sterile aqueous vehicle, the solution should be maintained at 4 °C and used within 5 to 7 days. Repeated freeze-thaw cycles following reconstitution should be avoided to preserve structural integrity.

For long-term laboratory inventory, individual aliquots should be prepared prior to reconstitution to minimize waste and degradation. All handling should be performed in a controlled laboratory environment by trained personnel using appropriate containment practices.

FAQ

Frequently Asked Questions

What receptor does ARA-290 primarily target in research models?+
ARA-290 is designed to interact with the innate-repair receptor (IRR), a heterodimer composed of the EPO receptor and the beta common receptor, rather than with the canonical erythropoietin receptor complex responsible for red blood cell production.
Does ARA-290 stimulate erythropoiesis in laboratory models?+
Published preclinical studies indicate that ARA-290 does not produce erythropoietic effects at the concentrations used for tissue-protective investigations, which is a key design feature separating it from full-length EPO.
What solvents are used to reconstitute ARA-290 in research settings?+
Researchers typically reconstitute lyophilized ARA-290 in sterile water for injection or phosphate-buffered saline at concentrations appropriate for the specific assay. The solvent choice is determined by the experimental protocol.
How is ARA-290 purity verified for research-grade material?+
Research-grade ARA-290 is verified by high-performance liquid chromatography (HPLC) to confirm purity of 99% or greater, and by mass spectrometry to confirm molecular identity.
Is ARA-290 approved for clinical or veterinary use?+
No. ARA-290 is supplied exclusively as a laboratory research compound and is not approved for clinical, veterinary, or any other non-research use.
More compounds

Related research compounds

BPC-157 research peptide vial — Optimum ReGen Peptides
BPC-157
Peptide Research Compound.
$35$7.00/mg
TB-500 research peptide vial — Optimum ReGen Peptides
TB-500
Thymosin Beta-4 Research Peptide.
$35$7.00/mg
Research library

ARA-290 research guides